Waning Immunity and Microbial Vaccines-Workshop of the National Institute of Allergy and Infectious Diseases.

Q2 Biochemistry, Genetics and Molecular Biology
Clinical and Vaccine Immunology Pub Date : 2017-07-05 Print Date: 2017-07-01 DOI:10.1128/CVI.00034-17
Xin-Xing Gu, Stanley A Plotkin, Kathryn M Edwards, Alessandro Sette, Kingston H G Mills, Ofer Levy, Andrea J Sant, Annie Mo, William Alexander, Kristina T Lu, Christopher E Taylor
{"title":"Waning Immunity and Microbial Vaccines-Workshop of the National Institute of Allergy and Infectious Diseases.","authors":"Xin-Xing Gu, Stanley A Plotkin, Kathryn M Edwards, Alessandro Sette, Kingston H G Mills, Ofer Levy, Andrea J Sant, Annie Mo, William Alexander, Kristina T Lu, Christopher E Taylor","doi":"10.1128/CVI.00034-17","DOIUrl":null,"url":null,"abstract":"<p><p>Since the middle of the 20th century, vaccines have made a significant public health impact by controlling infectious diseases globally. Although long-term protection has been achieved with some vaccines, immunity wanes over time with others, resulting in outbreaks or epidemics of infectious diseases. Long-term protection against infectious agents that have a complex life cycle and antigenic variation remains a key challenge. Novel strategies to characterize the short- and long-term immune responses to vaccines and to induce immune responses that mimic natural infection have recently emerged. New technologies and approaches in vaccinology, such as adjuvants, delivery systems, and antigen formulations, have the potential to elicit more durable protection and fewer adverse reactions; together with <i>in vitro</i> systems, these technologies have the capacity to model and accelerate vaccine development. The National Institute of Allergy and Infectious Diseases (NIAID) held a workshop on 19 September 2016 that focused on waning immunity to selected vaccines (for <i>Bordetella pertussis</i>, <i>Salmonella enterica</i> serovar Typhi, <i>Neisseria meningitidis</i>, influenza, mumps, and malaria), with an emphasis on identifying knowledge gaps, future research needs, and how this information can inform development of more effective vaccines for infectious diseases.</p>","PeriodicalId":10271,"journal":{"name":"Clinical and Vaccine Immunology","volume":"24 7","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2017-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1128/CVI.00034-17","citationCount":"34","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Vaccine Immunology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1128/CVI.00034-17","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2017/7/1 0:00:00","PubModel":"Print","JCR":"Q2","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}
引用次数: 34

Abstract

Since the middle of the 20th century, vaccines have made a significant public health impact by controlling infectious diseases globally. Although long-term protection has been achieved with some vaccines, immunity wanes over time with others, resulting in outbreaks or epidemics of infectious diseases. Long-term protection against infectious agents that have a complex life cycle and antigenic variation remains a key challenge. Novel strategies to characterize the short- and long-term immune responses to vaccines and to induce immune responses that mimic natural infection have recently emerged. New technologies and approaches in vaccinology, such as adjuvants, delivery systems, and antigen formulations, have the potential to elicit more durable protection and fewer adverse reactions; together with in vitro systems, these technologies have the capacity to model and accelerate vaccine development. The National Institute of Allergy and Infectious Diseases (NIAID) held a workshop on 19 September 2016 that focused on waning immunity to selected vaccines (for Bordetella pertussis, Salmonella enterica serovar Typhi, Neisseria meningitidis, influenza, mumps, and malaria), with an emphasis on identifying knowledge gaps, future research needs, and how this information can inform development of more effective vaccines for infectious diseases.

减弱的免疫力和微生物疫苗-国家过敏和传染病研究所研讨会。
自20世纪中叶以来,疫苗通过控制全球传染病,对公共卫生产生了重大影响。虽然某些疫苗已实现长期保护,但其他疫苗的免疫力会随着时间的推移而减弱,导致传染病的爆发或流行。对具有复杂生命周期和抗原变异的感染因子的长期保护仍然是一个关键的挑战。最近出现了描述对疫苗的短期和长期免疫反应并诱导模仿自然感染的免疫反应的新策略。疫苗学方面的新技术和新方法,如佐剂、递送系统和抗原制剂,有可能产生更持久的保护和更少的不良反应;与体外系统一起,这些技术具有模拟和加速疫苗开发的能力。国家过敏和传染病研究所(NIAID)于2016年9月19日举办了一次讲习班,重点关注对选定疫苗(百日咳博德泰拉、伤寒沙门氏菌、脑膜炎奈瑟菌、流感、腮腺炎和疟疾)免疫力下降的问题,重点是确定知识差距、未来的研究需求,以及如何利用这些信息为开发更有效的传染病疫苗提供信息。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Clinical and Vaccine Immunology
Clinical and Vaccine Immunology 医学-传染病学
CiteScore
2.88
自引率
0.00%
发文量
0
审稿时长
1.5 months
期刊介绍: Cessation. First launched as Clinical and Diagnostic Laboratory Immunology (CDLI) in 1994, CVI published articles that enhanced the understanding of the immune response in health and disease and after vaccination by showcasing discoveries in clinical, laboratory, and vaccine immunology. CVI was committed to advancing all aspects of vaccine research and immunization, including discovery of new vaccine antigens and vaccine design, development and evaluation of vaccines in animal models and in humans, characterization of immune responses and mechanisms of vaccine action, controlled challenge studies to assess vaccine efficacy, study of vaccine vectors, adjuvants, and immunomodulators, immune correlates of protection, and clinical trials.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信